Rituximab for psychosis linked to brain autoantibodies
Part of Mental health clinical trials.
This study tests whether a medication called rituximab can help people with psychotic symptoms that are linked to an autoimmune response (when the immune system attacks the brain). If you or your child have these antibodies, this treatment might reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults or children over 6 years old having a first episode or a relapse of psychotic symptoms (like hearing voices or having unusual beliefs).
- Must have specific antibodies in the blood that target the brain (called CNS autoantibodies).
- Must have a score greater than 3 on a symptom severity scale (MDC).
- If you have a history of heart disease, you need a recent normal ECG (heart tracing).
- Women who can have children must use effective contraception during treatment and for at least 12 months after the last dose of rituximab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests rituximab (an immune system medicine) to see if it can reduce OCD symptoms and/or psychosis when there are signs the immune system may be involved. You may be considered if other standard psychiatric treatments have not helped enough and your illness seems relatively recent with possible inflammation clues.
This trial tests whether rituximab, a medication that calms the immune system, can help people with certain nerve or brain conditions linked to a specific antibody. It aims to reduce symptoms or prevent the disease from getting worse.
This study looks at the levels of rituximab (a medicine that calms the immune system) and your body's response to it in people with certain autoimmune diseases. It may help doctors understand how to better adjust treatment.
This Phase 2 study tests whether bortezomib can improve outcomes and safety in adults with severe autoimmune encephalitis. It focuses on people whose condition is confirmed by brain-related autoantibodies and who have already received rituximab.
This trial tests whether a drug called rituximab can help children with their first episode of nephrotic syndrome stay in remission longer. It is for children who have already responded to steroid treatment.
This phase 1 trial tests whether rituximab (a drug that targets certain immune cells) can help reduce side effects caused by immunotherapy. The goal is to find a safe dose and see if it improves symptoms without harming your cancer treatment.
Hear when a new Mental Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.